Stockwinners Market Radar for December 27, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:07 EST ARK Investment bought 4.3M shares of ProShares Bitcoin Strategy ETF today

19:29 EST Hut 8 Corp. CEO sells $1.4M in common stock, CFO sells $253K in common stock - In regulatory filings, Hut 8 Corp disclosed that its CEO Jaime Leverton and CFO Shenif Visram sold 98.7K and 17.9K shares of common stock respectively on December 22nd in separate transactions of $1.4M an $253K.

17:58 EST Energy Fuels names Nathan Bennett Chief Accounting Officer and Interim CFO - Energy Fuels (UUUU):Tom Brock will cease to be the Chief Financial Officer of Energy Fuels effective December 31, Nathan Bennett, the current Corporate Controller of the Company, will be appointed as Chief Accounting Officer and Interim Chief Financial Officer of the Company effective January 1...Bennett, age 42, has served as the Company's Corporate Controller since August 25 . He previously served as Controller of Antero Midstream (AM) from December 2013 to August 2022, where he led the accounting, treasury, and financial reporting functions. Reference Link

17:35 EST SQM jumps 7% to $65.00 after disclosing memorandum of understanding with Codelco

17:20 EST Coinbase director sells $7.7M in common stock - In a regulatory filing, Coinbase disclosed that its director Frederick Ehrsam sold 43.7K shares of common stock on December 22nd in a total transaction size of $7.7M.

17:10 EST New Fortress Energy adds 1.6GW capacity reserve contract - New Fortress Energy announced that it has entered into a definitive agreement to acquire a 1.6 GW Capacity Reserve Contract from Ceiba Energy, a portfolio company of Denham Capital, in exchange for newly issued NFE redeemable Series A Convertible Preferred Stock and the assumption of certain liabilities from a subsidiary of Ceiba Energy. Following customary closing conditions including regulatory approval for the transfer of the PPA in Brazil, the PPA will contribute firm capacity payments of $280 million per annum through its 15-year contract life. NFE expects the transaction to close in March 2024, with project cash flows expected to begin no later than July 2026.

16:34 EST Gan Limited launches GAN Sports with Red Rock Resorts - GAN Limited (GAN) "announced that Red Rock Resorts, Inc. (RRR) has commenced field trials of GAN Sports under the STN Sports brand at all properties of Station Casinos LLC. The field trial commenced with the certification of GAN's GameSTACK 2.0 Platform. GAN Sports brings a seamless and innovative experience for players. The platform's utilization of a single wallet for race and sports allows players the ease and convenience of an accessible central location for their playing experience. The all-new STN Sports mobile app includes Nevada's largest wagering menu, same game parlay wagering options, higher parlay payouts, a single wallet for race and sports, and a variety of game-changing features set to roll out in early 2024."

16:24 EST Levi Strauss COO O'Neill sells $663K in company shares - Levi Strauss & Co COO Elizabeth O'Neill disclosed the sale of 38,975 shares of company stock at $17 per share on December 26, for a total transaction amount of $662,575.

16:20 EST Neurocrine director Lyons, Chief Medical Officer Roberts sell $1.3M in stock - In regulatory filings, Neurocrine disclosed that its director Gary Lyons and Chief Medical Officer Eiry Roberts each sold 10K shares of common stock on December 22nd in separate transactions of $1.3M.

16:18 EST Plexus notified that China subsidiary to be removed from BIS's Unverified List - Plexus Corp. received notification through official written correspondence from the U.S. Department of Commerce that its China subsidiary will be removed from the Bureau of Industry and Security's, or BIS, Unverified List. Through no fault of Plexus or the BIS, a delay in the routine verification of a shipment to Plexus Xiamen occurred, which as a result of strong cooperation between the organizations has now been swiftly rectified. The Department of Commerce has commenced an administrative process to publish the removal of Plexus from the Unverified List in the Federal Register, which the company anticipates to occur in January 2024. Plexus remains committed to compliance with all applicable U.S. export control laws, and to working with BIS in a transparent, collaborative manner.

16:15 EST SQM announces Memorandum of Understanding with Codelco - SQM announced that it reached a Memorandum of Understanding, or MOU, with the National Copper Corporation of Chile, or Codelco, for the operation and development of the Salar de Atacama during the period from 2025 to 2060. Reference Link

16:11 EST Lionsgate closes acquisition of eOne from Hasbro - Lionsgate (LGF.A) announced that it has closed its acquisition of the global entertainment platform eOne from Hasbro (HAS). Lionsgate acquired eOne for a purchase price of $375M in cash, subject to certain purchase price adjustments, plus the assumption of production financing loans. "The acquisition adds 6,500 film and television titles to Lionsgate's library, one of the largest and most valuable in the world, diversifies and strengthens its scripted and unscripted television businesses, extends its portfolio of brands and franchises and expands its presence in Canada and the UK. eOne produces the hit ABC franchise The Rookie, the critically-acclaimed Showtime series Yellowjackets and the long-running Discovery unscripted series Naked & Afraid. The transaction also includes film development rights to Hasbro's beloved Monopoly brand," Lionsgate said. "The eOne acquisition concludes a busy year in which we continued to execute our strategy of strengthening our studio business as we prepare for the separation of Lionsgate and STARZ into pure play standalone companies. As we've conducted our integration planning, our analysis has reaffirmed our conviction that eOne will be a valuable and highly accretive addition to our business. We are pleased to welcome eOne's talented group of employees to our Lionsgate family," said Lionsgate CEO Jon Feltheimer.

16:09 EST EG Acquisition, flyExclusive announce closing of business combination - flyExclusive, a provider of premium private jet charter experiences, and EG Acquisition Corp. (EGGF), a Special Purpose Acquisition Company sponsored by EnTrust Global and GMF Capital, announced the completion of their previously announced business combination. Upon the completion of the business combination, the combined company has been renamed flyExclusive, Inc. Beginning on December 28, the company's common stock are expected to begin trading on the NYSE American under the new ticker symbol "FLYX". The business combination was approved at a special meeting of EG Acquisition Corp.'s stockholders on December 18. "Today marks another milestone in our company's mission to elevate the private aviation experience," said Jim Segrave, Chief Executive Officer and founder of flyExclusive. "We built flyExclusive around the value that minutes matter for our customers, and this principle will continue to guide the disciplined approach that has defined our success in the industry." Gregg Hymowitz, CEO and Director of EG Acquisition Corp. and Chairman and CEO of EnTrust Global, added: "As we noted when the transaction was announced, flyExclusive has become one of the fastest-growing providers of premium private jet charter experiences thanks to their world-class leadership team, business model designed to maximize utilization and flight unit economics and the consistent high-quality service they provide to customers. We are excited that Jim and his team at flyExclusive have reached this stage and believe they are ready to further accelerate their market position as a public company."

16:05 EST Sigma Lithium says fifth shipment expected to leave port by year-end - Sigma Lithium announces the loading of "one last shipment" of 22,000 tonnes of concentrate to Glencore at the Port of Vitoria, noting that Sigma Lithium's fifth shipment is expected to leave port by year-end. "Glencore will prepay 50% of the fifth shipment's value upon completion of loading. The 50% prepayment reflects a provisional premium price for the Company's unique Quintuple Zero Green Lithium concentrate. Sigma Lithium has completed an incredible journey over the past twelve months, having gone from commissioning the crushing unit in December of 2022 on schedule and on budget, to sustaining nameplate production levels at its Greentech lithium concentrate plant in December 2023. Operating rates at these levels would support a monthly shipment cadence of roughly 22,000 tonnes through the course of 2024, annualizing approximately 270,000 tonnes of Quintuple Zero Green Lithium concentrate," the company stated. Sigma Lithium CEO, Ana Cabral-Gardner added, "We have a relentless, resilient team who has been working for years on a mission that has become our collective legacy: supporting the electric vehicle revolution by delivering the most sustainable lithium material in the world. In the process we became a better version of ourselves, transforming the lives of the people around us by providing economic empowerment, inclusion, citizenship. We are laying the foundation for common prosperity where metals, mining and metallurgical industries are fully embraced by communities as the drivers of technological and environmental innovation as well as positive social change. Our team has rarely set a foot wrong, nor missed our operational deadlines. We delivered on our promises, including those that seemed impossible at the time, such as achieving Carbon Neutrality / Net Zero 27 years ahead of the metal and mining industry."

15:27 EST FTC sues Grand Canyon University, alleging deceptive advertising - The Federal Trade Commission has filed suit against Grand Canyon Education, Grand Canyon University, and Brian Mueller - the CEO of GCE and president of GCU - for "deceiving prospective doctoral students about the cost and course requirements of its doctoral programs and about being a nonprofit, while also engaging in deceptive and abusive telemarketing practices," the FTC announced. The FTC's complaint also says that, despite operating the school for the profit of GCE and its investors, the defendants deceptively marketed the school as a nonprofit. The FTC alleges that GCU has been operated for the profit of GCE and its stockholders, and pays 60% of its revenue to GCE pursuant to an agreement designating GCE as the exclusive provider for most university-related services. Even though he serves as GCU's president, Mueller also benefits as both CEO and a stockholder of GCE, and receives bonuses tied to GCE's performance. The complaint was filed in the U.S. District Court for the District of Arizona. Reference Link

14:50 EST American Electric subsidiaries seek approval of settlement in fuel cost cases - American Electric Power subsidiaries Appalachian Power and Wheeling Power filed a settlement agreement with the Public Service Commission of West Virginia, or PSC, that addresses the companies' Expanded Net Energy Cost, or ENEC, cases. "The agreement outlines a process for recovering deferred fuel and purchased power costs, major storm restoration expenses, power plant balances and environmental compliance project expenses through securitization. The West Virginia Energy Users Group and the West Virginia Coal Association joined Appalachian Power and Wheeling Power in signing onto the agreement. The settlement is subject to review and approval by the PSC," the company stated. "If approved by the Commission, this settlement agreement will benefit our West Virginia customers by spreading out the recovery of these necessary costs to help keep customer bills affordable and support a reliable energy system," said Peggy Simmons, AEP's executive vice president of Utilities. As part of the settlement, Appalachian Power and Wheeling Power agreed to reduce their requested fuel deferral amount by $50M to minimize the impact on customers. The agreement proposes to utilize West Virginia's utility securitization law to address approximately $1.9B in costs. This is a new option approved in the 2023 legislative session, with broad support, to address customer affordability. Securitization enables these costs to be recovered over a much longer timeframe, mitigating the impact on customer bills. Securitization will not affect the retirement of Appalachian Power's and Wheeling Power's coal plants, and the companies intend to run those plants, which benefit West Virginia customers and support grid reliability, through the end of their useful lives. The securitization plan will be filed by Appalachian Power and Wheeling Power and will be subject to review and approval by the PSC.

13:33 EST Edgewise Therapeutics rises after Cytokinetics succeeds in HCM trial - Shares of Edgewise Therapeutics (EWTX) are up greater than 25% after another drugmaker exploring the same space reported success in a clinical trial. Shares of Cytokinetics (CYTK) are sharply higher in midday trading after the company announced topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, or HCM, a condition that makes it hard for the heart to pump blood. "The results from SEQUOIA-HCM meet our high expectations for both efficacy and safety, demonstrating that aficamten added to standard of care therapy had a positive impact on exercise capacity as well as rapid and sustained effects on symptoms and functional class in patients with obstructive HCM while maintaining the safety and tolerability that we have previously observed. We believe these results are consistent with those observed in REDWOOD-HCM, the Phase 2 clinical trial of aficamten, and FOREST-HCM, the ongoing open label extension clinical trial, and may reflect a profile enabling of aficamten to become the cardiac myosin inhibitor of choice among physicians and patients," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. In mid-September, Edgewise Therapeutics announced initial dosing in a Phase 1 trial of EDG-7500, an oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other diseases of diastolic dysfunction. The Phase 1 trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of EDG-7500 in healthy adults. The company is also planning to begin a Phase 1b study of EDG-7500 in individuals with obstructive HCM in the first half of 2024. Near 1:30 pm ET, Edgewise shares have gained $2.48, or 26%, to $12.00, while Cytokinetics shares have jumped $35.97, or nearly 79%, to $81.68.

13:04 EST Nxu Inc. executes partnership, investment in Lynx Motors - Nxu, Inc. has executed definitive documents to finalize its strategic investment in Lynx Motors. The financial impact of the transaction results in an increase in Nxu's shareholder equity and helps to ensure that Nxu can achieve and maintain Nasdaq's continued listing standards by and beyond Nasdaq's extension deadline of April 7, 2024. Nxu's investment is structured as a share exchange, whereby $3M in Nxu shares will be exchanged for $3M in Lynx shares. The value of Lynx shares become an asset on the Company's balance sheet. Additionally, Nxu now holds one seat on Lynx's Board of Directors, allowing the Company a hands-on opportunity to help develop Lynx and monitor the status of its investment. To expedite the electrification process, Lynx has issued an interest-free promissory note of $250,000 to Nxu in exchange for a $250,000 bridge loan. The Agreement is subject to registration rights and representations and warranties that survive the closing.

12:08 EST Salem Media announces new $26M revolving credit facility with Siena Lending - Salem Media Group announced that it has closed a new $26.0M 3-year asset-based revolving credit facility with Siena Lending Group, which refinanced its prior revolving facility with Wells Fargo Bank. "Obligations under the New Revolving Facility are secured by a first-priority lien on the company's and its subsidiaries' accounts receivable, inventory, deposit and securities accounts, certain real estate and related assets, and a second-priority lien on substantially all other assets of the company and its subsidiaries," Salem Media stated.

12:00 EST Wheels Up rises 24.5% - Wheels Up is up 24.5%, or $1.03 to $5.23.

12:00 EST AGFiQ US Market Neutral Anti-Beta Fund falls -6.3% - AGFiQ US Market Neutral Anti-Beta Fund is down -6.3%, or -$1.11 to $16.64.

12:00 EST Time Inc. falls -17.1% - Time Inc. is down -17.1%, or -$4.36 to $21.18.

11:47 EST Belite Bio receives approval for Phase 3 geographic atrophy trial in China - Belite Bio announced earlier today the approval from the National Medical Products Administration to initiate the Phase 3 clinical trial of Tinlarebant for geographic atrophy, or the PHOENIX study, in China. The PHOENIX study is a Phase 3, multicenter, double-masked, placebo-controlled, randomized, fixed-dose clinical study designed to evaluate the efficacy and safety of tinlarebant in patients with GA associated with dry age-related macular degeneration. To date, the company has commenced the PHOENIX study in the U.S., Taiwan, Australia, UK, and Switzerland.

11:22 EST FCCPC says British American Tobacco agreed to pay $110M in consent order - FCCPC Nigeria, the competition and consumer protection agency of the Federal Government of Nigeria announced in a tweet: "In resolution of an investigation over a broad range of anticompetitive conduct including abuse of dominance, seeking to frustrate competitors, penalise retailers for providing equal platforms for product display of competitors, product introduction in violation of regulations among others, & infringement of public health control regulations British American Tobacco & FCCPC entered into a consent order including a penalty of $110 Million during 2023." Reference Link

10:00 EST MBIA falls -6.4% - MBIA is down -6.4%, or -43c to $6.24.

10:00 EST Time Inc. falls -17.0% - Time Inc. is down -17.0%, or -$4.34 to $21.20.

10:00 EST BIT Mining rises 13.1% - BIT Mining is up 13.1%, or 75c to $6.47.

09:50 EST Nio closes $2.2B equity investment from CYVN, as announced on December 18 - Earlier today, the company stated: "NIO announced that it has closed the $2.2 billion strategic equity investment from CYVN Investments RSC Ltd, an investment vehicle based in Abu Dhabi, as announced on December 18, 2023. In July 2023, CYVN made a $738.5 million strategic equity investment in the Company and acquired certain Class A ordinary shares of the Company from an affiliate of Tencent Holdings Ltd. for an aggregate consideration of US$350 million. Both transactions were closed in July 2023. Now with the closing of the US$2.2 billion strategic equity investment, CYVN in aggregate beneficially owns approximately 20.1% of the Company's total issued and outstanding shares. Going forward, NIO and CYVN, together with their respective affiliates, will continue to work closely and jointly to pursue strategic and technology collaborations in international markets."

09:47 EST Burford Capital rises 9.3% - Burford Capital is up 9.3%, or $1.26 to $14.77.

09:47 EST AGFiQ US Market Neutral Anti-Beta Fund falls -5.9% - AGFiQ US Market Neutral Anti-Beta Fund is down -5.9%, or -$1.04 to $16.71.

09:47 EST Time Inc. falls -16.8% - Time Inc. is down -16.8%, or -$4.28 to $21.26.

09:43 EST Knightscope announces contract expansion for three K1 Blue Light Towers - Knightscope announces an expansion contract for 3 K1 Blue Light Towers with a public transportation provider located in Texas, bringing the total number of Towers purchased to 13. In addition, contracts for the Knightscope Emergency Management System, a full-service maintenance program and a 2-year voice and data plan were signed to cover all 13 devices.

09:41 EST Chavant Capital Acquisition Corp trading resumes

09:37 EST Co-Diagnostics completes submission on Co-Dx PCR Pro to FDA - Co-Diagnostics has submitted its Co-Dx PCR COVID-19 test with Co-Dx PCR Pro instrument for review by the U.S. Food and Drug Administration for Emergency Use Authorization. The submission includes the PCR Pro instrument, COVID-19 detection test, and mobile app, all designed for use in point-of-care and at-home settings. Tests run on the new platform use the Company's patented real-time polymerase chain reaction Co-Primers technology. The Co-Dx COVID-19 test kit for the PCR Pro instrument included in the Company's FDA submission has been shown in clinical evaluations to detect the presence of COVID-19 in anterior nasal swab samples, with results displayed on the user's smartphone or mobile device in approximately 30 minutes.

09:35 EST Verb Technology CEO says 'primed for success' as company enters 2024 - Verb Technology Company announced VERB CEO Rory Cutaia has issued a year-end letter to its stockholders, which read in part, "2023 began with our Board and senior management team already engrossed in the all-consuming process of selling our SaaS business division assets, an almost 9-month long endeavor, marked by endless business presentations, ongoing due diligence and negotiation sessions, as well as associated legal, accounting, and regulatory matters, culminating in an offer from the successful bidder that was accepted by our Board. Following the closing of the sale last June, we began in earnest to focus all of our energies and resources on our MARKET.live livestream social selling business with our newly constituted management team that was now comprised of approximately 80 fewer people than we had before the sale. And yet, this newly energized team accomplished more in the past 6 months than we had in what feels like the prior 2 years combined...As we disclosed earlier this year, we executed a letter of intent to acquire certain revenue generating assets we believed were complimentary to our MARKET.live business objectives from certain parties with whom we were engaged for other aspects of our MARKET.live business. However, after many months of due diligence, we concluded that the opportunity, as well as the relationship were not the right fits for our business, and we recently terminated both. As we began the relationship with TikTok and launched our technology integration, we experienced almost immediate, rapid growth, recognized by TikTok, as referenced above, as being among the top producers. However, that growth revealed flaws in a key partner's supply chain whose capabilities fell far short of their representations. This forced us to pull back for almost 10 weeks while we sourced replacement suppliers and finalized other partnerships we had been working on. Fortunately, those new relationships are now in place, required technology integrations complete, and performance capabilities tested, allowing us to look forward to 2024 with great optimism and excitement. Especially so now, as our team experienced first-hand how rapidly the growth came once we completed the technology integration with TikTok and opened the faucet. Within a few short weeks we had developed a stable of more than 1600 TikTok affiliates who signed on to sell MARKET.live vendors' products. With the new vendor and supplier relationships in place, we are now beginning to rebuild that stable of TikTok affiliates, which could be akin to a massive army of sales reps, selling MARKET.live products to their own fans and followers. Of course I recognize that we are all disappointed with the current share price caused by a combination of unprecedented, prolonged poor capital markets conditions and the corresponding machinations of bad actors. However, share price has very little to do with the value a strategic buyer places on the business in a sale. Accordingly, while we have virtually no control over market conditions and the share price, we do have control over the intrinsic value we are creating as evidenced by the long list of achievements detailed above. As such, we believe our long-term investors may have an opportunity to generate returns that are not reflected in the share price alone. These achievements represent our relentless pursuit of excellence and innovation as well as our unstoppable determination and perseverance to overcome any obstacle, and any challenge, and there have been many. As we begin 2024, we are primed for the success we and you have surely earned and deserve."

09:30 EST Angion Biomedica Corp trading halted, volatility trading pause

09:19 EST Pioneer Power receives four new orders valued at over $10M - Pioneer Power Solutions announced that it has received four new orders, as further described below, valued in excess of $10M in the aggregate for its e-Bloc and related products. The Company expects to deliver and install these orders beginning in the second quarter of 2024. Nathan Mazurek, Pioneer's Chairman and Chief Executive Officer, said, "Increasingly, we are converting our pipeline of new business opportunities into sales, and these orders announced today further increase our expected revenue for 2024 and into 2025. The distributed power generation market is lacking solutions that can meet the consumption needs of industrial and commercial customers. Demand is extremely robust, and we continue to evolve our platforms to address the increasing demand." An EV charging infrastructure developer awarded Pioneer Power a contract to provide the double ended substation for the EV charging platform at a site located in Rialto, California. The customer is expected to deploy the solution at additional sites over the course of the next 12 months. This customer provides turnkey solutions for charging infrastructure and services to enable fleets to transition to electric transportation. We believe Pioneer's distributed power grid solution will allow for easy installation and access to power the EV charging platform. The Company expects the order will be completed and delivered in the second quarter of 2024.

09:10 EST Horizonte Minerals announces signing of $20M funding package - Horizonte Minerals has agreed a $20 million interim funding package which comprises a $15 million Senior Secured Loan Facility, and the release of $5 million by OMF Fund III previously secured at Vermelho, that will allow for critical construction streams to advance at its flagship Araguaia Nickel Project and for general working capital purposes. The Facility has been provided by OMF Fund III, La Mancha Investments and Glencore International who have each committed $5 million to the Facility. The New Money Lenders will rank pari passu with the Senior Lenders and will benefit from the same security package. The Facility will have a maturity date falling 102 months from 7 December 2022 and will bear interest at 15.00% per annum. Furthermore, the existing Senior Lenders have agreed to waivers that include deferral of interest due at 31st December 2023 to the end of February 2024 in addition to any breaches or Events of Default under the Senior Debt Facilities. The Funding Package constitutes a related party transaction under Rule 13 of the AIM Rules for Companies. As such, the Company's independent directors consider, having consulted with its nominated adviser Peel Hunt LLP, that the terms of the Funding Package are fair and reasonable insofar as its shareholders are concerned. Further to the above, OMF Fund III Ltd. has demonstrated its further support to the Project through the release of an additional $5 million currently secured at Vermelho, Horizonte's second 100% owned project in Brazil. Following the closing of the funding package, $11 million will remain segregated for the development of Vermelho, where on-going studies continue to advance. The Funding Package provides the Company with liquidity to advance the required re-estimation work at Araguaia, necessary to implement a full funding solution. It will also allow two critical workstreams to be completed, the Water Storage Reservoir and the 230kV powerline, while maintaining a strong focus on safety.

09:07 EST Wrap Technologies receives $4.9M BolaWrap order in Q4 - Wrap Technologies announces a landmark milestone in its history, having received a $4.9M BolaWrap order for the fourth quarter of 2023. This deal represents the largest order in Company history and signifies the first step in what the Company anticipates will be a large global deployment opportunity for WRAP's solution set in 2024.The order is expected to also support WRAP's ongoing efforts to scale its production infrastructure, accelerate research and development initiatives, and enhance customer support.

09:03 EST La Rosa Holdings acquires 51% interest in franchisee La Rosa Realty Orlando - La Rosa Holdings announced that it has acquired a 51% interest in the Company's franchisee - La Rosa Realty Orlando located in Orlando, Florida. Realty Orlando generated revenue of $3.6M and had positive net income in 2022. The franchisee provides residential and commercial real estate brokerage services. It also provides coaching and support services to agents on a fee basis. Joe La Rosa, CEO of the Company, commented, "We are excited to close on this acquisition. Even though we are currently in a down market, Realty Orlando was able to achieve approximately a 14% increase in total transactions closed for 2023 compared to 2022. We believe this is due to our unique brokerage model, which offers real estate agents the option of a revenue share model or an annual fee-based model with 100% agent commissions, which, in our view, is second to none in the industry. We are executing towards our goal of reaching an annualized revenue run rate of $100M before the end of 2024, and have several more franchisees in the pipeline that we plan on acquiring over the next several months."

09:01 EST Bluejay Diagnostics begins multicenter clinical study of Symphony IL-6 test - Bluejay Diagnostics announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients. The Symphony System is designed to address the need for simple, reliable, rapid, near-patient testing by providing quantitative measurements of specific biomarkers to determine the need for additional patient care and monitoring. The Symphony System was shown in published clinical studies to deliver results directly from whole blood in approximately 20 minutes. This study will use the Symphony IL-6 test to monitor IL-6 concentrations in patients who are diagnosed with sepsis or septic shock and are admitted or intended to be admitted to the ICU. The objective of this study is to establish IL-6 concentrations in these sepsis patients that best predict 28-day mortality.

08:58 EST Trinity Biotech begins shipments of HIV screening test to Kenya - Trinity Biotech has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV. The Kenyan HIV screening programme is one of the largest in Africa, with an estimated 10 million HIV screening tests performed annually. The Company has begun commercial shipments as part of the initial purchase order the Company received for 2.5 million tests, with further shipments under that purchase order scheduled for early 2024. Trinity understands that the Kenyan Ministry of Health has received commitments from all relevant sponsors to fund the procurement from the Company of all 10 million rapid screening HIV tests required by Kenya for 2024, and the Company expects to receive and fill additional purchase orders during 2024. The implementation of the new HIV testing algorithm, that includes TrinScreen HIV, is expected to start in January 2024.

08:52 EST LQR House enters marketing partnership with Don Ramon Tequila - LQR House announced its latest collaboration with Casa Don Ramon. This strategic partnership aims to elevate the visibility and sales of Casa Don Ramon's high-quality tequila and mezcal through innovative viral content creation. The impact of this marketing agreement will be closely monitored to assess its direct influence on sales for Casa Don Ramon products on LQR House's ecommerce platform, CWSpirits.com.

08:46 EST New York Times sues OpenAI, Microsoft over copyright infringement - The New York Times (NYT) has filed a copyright infringement suit against OpenAI and Microsoft (MSFT), arguing that millions of the publication's articles were used to train automated chatbots that now compete with The Times as a source of reliable information, the New York Times' Michael Grynbaum and Ryan Mac report. The suit does not include a specific monetary demand, but stated the defendants should be held responsible for "billions of dollars in statutory and actual damages" related to the "unlawful copying and use of The Times's uniquely valuable works." It also calls on the companies to destroy any chatbot models and training data that use copyrighted material. Reference Link

08:42 EST Freight Technologies announces conversion of $3.55M convertible debt - Freight Technologies announces conversion by investors of convertible debt to equity. Investors in the Company's convertible notes have converted approximately $3.55 million in convertible notes into equity in the form of preferred shares.

08:40 EST Royalty Management forms critical mineral, lithium inventory financing division - Royalty Management Holding has established a division of the Company that focuses on investment and development of the domestic energy storage and energy efficiency markets, with an initial focus on investing in the raw material supply chain of critical minerals by financing the creation of feedstock inventories from sources around the globe, to be later used in the refining of these strategic materials into high-grade materials for the creation of products focused on energy storage and efficiency, such as batteries and high-efficiency, permanent magnets. RMCO anticipates initiating several investments within this newly formed division throughout 2024.

08:36 EST Vistagen announces EPO notice of intention to grant patent to AV-101 for pain - Vistagen announced that the European Patent Office EPO issued a Notice of Intention to Grant a patent related to the use of AV-101 for the treatment of neuropathic pain. AV-101 is the Company's investigational oral prodrug of 7-chloro-kynurenic acid or 7-Cl-KYNA, a potent and selective full antagonist of the glycine coagonist site of the N-methyl-D-aspartate receptor NMDAR . The patent, once granted, will not expire until at least 2034 and will become part of Vistagen's global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

08:36 EST Codexis reports purchase agreement with Nestle Health Science for CDX-7108 - Codexis (CDXS) announced it has entered into a purchase agreement with Nestle Health Science for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency, or EPI. Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Codexis will receive up to an additional $5M if Nestle Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI. Nestle Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs. Codexis and Nestle Health Science completed pre-clinical work for CDX-7108 and a Phase I clinical trial under the terms of a previous agreement. With this asset purchase agreement, Nestle Health Science may continue advancing the compound through the development process. Nestle Health Science is a globally managed business unit of Nestle (NSRGY).

08:35 EST Codexis enters into purchase agreement with Nestle Health Science for CDX-7108 - Codexis (CDXS) announced it has entered into a purchase agreement with Nestle Health Science for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency, or EPI. Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Codexis will receive up to an additional $5M if Nestle Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI. Nestle Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs. Codexis and Nestle Health Science completed pre-clinical work for CDX-7108 and a Phase I clinical trial under the terms of a previous agreement. With this asset purchase agreement, Nestle Health Science may continue advancing the compound through the development process. Nestle Health Science, a leader in the science of nutrition and gastrointestinal health, is a globally managed business unit of Nestle (NSRGY).

08:34 EST Codexis enters into pruchase agreement with Nestle Health Science for CDX-7108 - Codexis (CDXS) announced it has entered into a purchase agreement with Nestle Health Science for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insufficiency, or EPI. Under the terms of the agreement, Codexis will receive up to $45M in potential milestone payments, including a $5M upfront payment, as well as single-digit net-sales-based royalties. Codexis will receive up to an additional $5M if Nestle Health Science exercises an option to purchase two additional early-stage enzymes being developed for EPI. Nestle Health Science will be solely responsible for the continued development and commercialization of CDX-7108, including all associated costs. Codexis and Nestle Health Science completed pre-clinical work for CDX-7108 and a Phase I clinical trial under the terms of a previous agreement. With this asset purchase agreement, Nestle Health Science may continue advancing the compound through the development process. Nestle Health Science, a leader in the science of nutrition and gastrointestinal health, is a globally managed business unit of Nestle (NSRGY).

08:33 EST Surf Air Mobility names Oliver Reeves CFO - Surf Air Mobility announced that Oliver Reeves will join the company as CFO. Reeves will lead the company's financial and capital markets strategies leveraging his nearly two decades of experience in the investment management, enterprise technology, and insurance industries. He will start his new role in January, 2024. Reeves recently worked at Xinuos, Inc., where he served as the chief strategy officer since 2019.

08:30 EST Williams to acquire natural gas storage portfolio from Hartree for $1.95B - Williams announced that it has reached an agreement to acquire a portfolio of natural gas storage assets from an affiliate of Hartree Partners LP for $1.95B. The transaction includes six underground natural gas storage facilities located in Louisiana and Mississippi with total capacity of 115B cubic feet, or Bcf, as well as 230 miles of gas transmission pipeline and 30 pipeline interconnects to attractive markets, including LNG markets, and connections to Transco. The acquisition price represents an approximate 10x estimated 2024 EBITDA multiple. The six natural gas storage facilities include four salt domes with combined capacity of 92 Bcf and two depleted reservoirs with combined capacity of 23 Bcf. The facilities have injection capacity of 5 Bcf/d and withdrawal capacity of 7.9 Bcf/d, among the highest of any natural gas storage platform in the United States. Two of the facilities, Pine Prairie and Southern Pines, are directly connected with Transco and are well positioned for expansions. The transaction is expected to close in January 2024, following satisfaction of customary closing conditions, including the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

08:17 EST Trulieve Cannabis to open Florida dispensaries in Crawfordville, Crestview - Trulieve Cannabis announced the opening of two new medical dispensaries in Crawfordville and Crestview, Florida. "We are excited to open these dispensaries, providing high quality products and service for Florida patients in the Big Bend and Panhandle regions," said Trulieve's Chief Executive Officer Kim Rivers.

08:11 EST Medigus:Charging Robotics announces results of high voltage electricity transfer - Medigus announced that Charging Robotics has completed an important milestone towards the installation of its wireless charging system in automatic car parks as part of its pilot program with an automatic car park provider in Israel. This milestone included a successful experiment for transferring high voltage electricity in a wireless manner needed for electric vehicle charging. The experiment was conducted in order to verify that the proprietary voltage and current control algorithms developed by Charging Robotics are capable of controlling the voltage and current within the required limits. The experimental system included two resonance coils designed and manufactured by Charging Robotics. These coils were held at an air gap distance of 40mm. The electricity was transferred from one coil to the other by means of electromagnetic induction. The source for the electricity was a direct current electricity power supply fed from 3 phase grid power sources. The DC power was converted to alternating current at resonance frequency using a power circuit designed by Charging Robotics that fed the transmitting coil. From the receiving coil, the induced power was converted from AC to DC using a similar power circuit. All algorithms needed for the control of the system were developed by Charging Robotics. This successful experiment will enable the pilot program to progress to the next step, which is the full charging of an EV using the wireless charging system developed by Charging Robotics at a higher voltage. If the next trial is successful it will be followed by the installation of the system at the automatic car park to be used for wirelessly charging EVs.

08:07 EST WiMi Hologram Cloud builds blockchain heterogeneous computing framework - WiMi Hologram Cloud announced that by combining cloud servers, general-purpose computers, and FPGAs, WiMi has built a blockchain heterogeneous computing framework named "HeteroBlock Framework". The framework is designed to provide users with efficient, flexible, and reliable blockchain computing services to meet the growing computing demand. The core of the HeteroBlock framework lies in its ability to handle heterogeneous nodes. In the traditional isomorphic blockchain computing method, all nodes have the same computing capability, which limits the performance and scalability of the blockchain to a certain extent. In contrast, the HeteroBlock framework makes full use of the advantages of various nodes by assigning different computational tasks to heterogeneous nodes, which realizes more efficient and economical computational capabilities. This not only improves the utilization of computing resources but also brings more possibilities for blockchain applications. With the support of the HeteroBlock framework, blockchain can be better adapted to a variety of scenarios, ranging from financial transactions to supply chain management, and from digital identity verification to IoT device interaction. The HeteroBlock framework provides a new way of computing for general-purpose computing nodes and heterogeneous nodes, combining with related communication protocols and software algorithms to improve the structure of the blockchain network, and providing a powerful infrastructure for the deployment of smart contracts and the execution of computational tasks. HeteroBlock framework, by combining it with a variety of communication protocols and software algorithms, provides blockchain applications with more flexible and powerful support. support. In addition, the framework reduces computation costs by optimizing the allocation and execution of computation tasks, making it possible to apply blockchain technology in more fields.

08:06 EST NKGen Biotech receives NOL in Canada for SNK01 study - NKGen Biotech announced that it has received a No Objection Letter, or NOL, from Health Canada for its Clinical Trial Application, or CTA, for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer, or NK, cell therapy for treatment of patients with moderate Alzheimer's Disease, or AD. SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression. Phase 1 is an open label safety evaluation to determine the maximum tolerated dose and/or recommended Phase 2 dose of SNK01. Phase 2 is a randomized, placebo controlled, multicenter trial evaluating the safety and efficacy of SNK01 in moderate AD patients. This approved trial of approximately 36 patients with moderate AD is expected to commence in December 2023 with the first interim data expected in Q3 2024.

08:04 EST Where Food Comes From acquires the Upcycled Certified Program - Where Food Comes From announced it has acquired the Upcycled Certified Program from the Upcycled Food Association. Upcycled Certified, the world's first and largest provider of certification for upcycled food, has emerged as a dynamic force that is reshaping the way manufacturers valorize all parts of the food chain and avoid food waste. Upcycled Certified is now one of the fastest-growing certification seals in the food industry, providing consumers a tangible solution to shop sustainably. There are currently 93 companies with more than 480 products certified to the standard, including leading Consumer Packaged Goods companies such as Del Monte and Kerry Ingredients. These products are responsible for diverting an average of 390,000 tons of food waste annually since the Program's launch less than three years ago. The Upcycled Standard, developed by the Upcycled Food Association, is designed to reduce food waste by promoting the upcycled food economy. Upcycled products use ingredients that have full nutritional value and are safe but for various reasons would have gone to waste. Operators that grow, produce, manufacture, process, and trade in food, beverages and other food-related products are eligible to apply for Upcycled Certified.

08:03 EST Moleculin Biotech CEO buys $130K in common stock - In a regulatory filing, Moleculin Biotech disclosed that its CEO Walter Klemp bought 188K shares of common stock on December 26th in a total transaction size of $130K.

08:00 EST Landsea Homes launches first environmental, social, governance report - Landsea Homes Corporation published its first environmental, social and governance report, which details the Company's ongoing environmental and sustainability initiatives as well as diversity, equity, and inclusion efforts. "Since our founding, sustainability has been one of our guiding principles and highest priorities. Our commitment to acting with integrity, supporting our team, building thriving communities, and exercising environmental stewardship have long been embedded within strategic planning across our business operations to create long-term value for our stakeholders," said John Ho, Chief Executive Officer, Landsea Homes. "Each year, we strive to improve and increase our implementation of the latest sustainable innovations to provide our homebuyers with cutting-edge designs, a healthier lifestyle, and best-in-class, energy-efficient homes."

07:38 EST Cytokinetics jumps 43% after reporting results of study of aficamten in HCM - Shares of Cytokinetics are up $19.73, or 43%, to $65.44 in pre-market trading after the company announced topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, or HCM. "The results from SEQUOIA-HCM meet our high expectations for both efficacy and safety, demonstrating that aficamten added to standard of care therapy had a positive impact on exercise capacity as well as rapid and sustained effects on symptoms and functional class in patients with obstructive HCM while maintaining the safety and tolerability that we have previously observed. We believe these results are consistent with those observed in REDWOOD-HCM, the Phase 2 clinical trial of aficamten, and FOREST-HCM, the ongoing open label extension clinical trial, and may reflect a profile enabling of aficamten to become the cardiac myosin inhibitor of choice among physicians and patients," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development.

07:36 EST Matinas announces results from two LNC-formulated oligonucleotides studies - Matinas BioPharma Holdings announces results from a series of in vivo studies demonstrating successful oral delivery of two LNC-formulated small single-strand oligonucleotides that specifically target key inflammatory cytokines TNFalpha and IL-17A in well-established and validated animal models that mimic acute inflammatory responses seen in human diseases. "These studies demonstrate successful oral delivery and biological activity of two different LNC-formulated small oligonucleotides targeting inflammatory cytokines with reductions in tissue cytokine mRNA in both colitis and psoriasis, along with significant reductions in serum TNFalpha levels in colitis. Commensurate improvements in clinical disease markers and scores were also documented in both models," said James Ferguson, Matinas' Chief Medical Officer. Earlier this year, Matinas established the in vitro potency of these proprietary oligonucleotides and their LNC formulations in knocking down their respective cytokine targets in cultured cells. Both were advanced to in vivo studies to evaluate meaningful biological activity in relevant disease models.

07:33 EST Cytokinetics reports topline results from SEQUOIA-HCM Phase 3 trial - Cytokinetics announced topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. The results of SEQUOIA-HCM show that treatment with aficamten significantly improved exercise capacity compared to placebo, increasing peak oxygen uptake measured by cardiopulmonary exercise testing by a least square mean difference of 1.74 mL/kg/min. The treatment effect with aficamten was consistent across all prespecified subgroups reflective of patient baseline characteristics and treatment strategies, including patients receiving or not receiving background beta-blocker therapy. Statistically significant and clinically meaningful improvements were also observed in all 10 prespecified secondary endpoints, including Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at weeks 12 and 24, the proportion of patients with greater than or equal to1 class improvement in New York Heart Association functional class at weeks 12 and 24, change in provoked left ventricular outflow tract gradient and proportion less than30 mmHg at weeks 12 and 24, as well as exercise workload and guideline-eligibility for septal reduction therapy. Aficamten was well-tolerated in SEQUOIA-HCM with an adverse event profile comparable to placebo. Treatment emergent serious adverse events occurred in 8 and 13 patients on aficamten and placebo, respectively. Core echocardiographic left ventricular ejection fraction was observed to be less than50% in 5 patients on aficamten compared to 1 patient on placebo. There were no instances of worsening heart failure or treatment interruptions due to low LVEF.

07:16 EST Wearable Devices announces increase in production of Mudra Band - Wearable Devices announced a significant increase in the production of its Mudra Band. This strategic move aims to meet the anticipated interest following the Company's showcase at the upcoming 2024 Consumer Electronic Show event.

07:11 EST Iovance Biotherapeutics reports FDA clinical hold on IOV-LUN-202 trial - Iovance Biotherapeutics announced a clinical program update for LN-145 TIL therapy in non-small lung cancer. The U.S. Food and Drug Administration placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen. IOV-LUN-202 is investigating LN-145 in patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced non-small cell lung cancer without EGFR, ROS or ALK genomic mutations and had received at least one line of an FDA-approved targeted therapy if indicated by other actionable tumor mutations. These patients have a poor prognosis, limited treatment options, and a real-world overall survival of less than six months. The clinical hold for IOV-LUN-202 has no impact on any other Iovance clinical trials and is independent of the FDA's Priority Review of the biologics license application for lifileucel in advanced melanoma. The BLA remains on track toward the Prescription Drug User Fee Act action date of February 24, 2024. Iovance will pause enrollment and the LN-145 TIL treatment regimen for new patients in IOV-LUN-202 during the clinical hold. Patients previously treated with LN-145 in the IOV-LUN-202 trial will continue to be monitored and followed according to the trial protocol. Patients who have already undergone tumor resection will continue to receive the LN-145 TIL treatment regimen with additional precautions and risk mitigations. Preliminary data for IOV-LUN-202 was reported in July of 2023. An updated analysis in November of 2023 showed additional ongoing responses and duration of response greater than six months for 71% of the confirmed responders in the trial. These results from IOV-LUN-202 in previously treated patients with advanced NSCLC continue to support the potential benefit of one-time TIL therapy, including the opportunity for more durable responses than available second line chemotherapies. Iovance is committed to

07:05 EST Plug Power completes installation of electrolyzer system at Amazon center - Plug Power (PLUG) completed the installation and commissioning of an electrolyzer system at an Amazon (AMZN) fulfillment center in Aurora, Colorado. The one-megawatt proton exchange membrane electrolyzer is the first for Amazon and is producing low-carbon hydrogen to fuel more than 225 hydrogen fuel cell-powered forklift trucks at the site, known as DEN8. The Plug 1MW electrolyzer, which uses electricity and water to produce hydrogen, is able to support up to 400 hydrogen fuel cell-powered forklift trucks. The hydrogen produced by the electrolyzer will be compressed on site and stored in a gaseous hydrogen storage tank for use by the forklift trucks.

07:03 EST Synlogic awarded $1M subcontract with Air Force Research Lab - Synlogic announced that it has entered into an approximately $1M subcontract under an Air Force Research Lab, or AFRL, prime contract to develop a manufacturing process to support development of a potential live probiotic product. The grant is an extension of work initiated by Synlogic in 2020 as part of the Air Force Synthetic Biology Challenge with the Massachusetts Institute of Technology. Synlogic's activities on this project are expected to start in Q1 2024 and will be complete in Q1 2025.

07:02 EST Avalo Therapeutics announces a 1-for-240 reverse stock split - Avalo Therapeutics announced a 1-for-240 reverse stock split of the Company's common stock, par value 1c, which will be effective at 5:00 pm Eastern Time on December 28. The Company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis beginning on December 29 under the Company's existing trading symbol "AVTX". The Company is implementing the reverse stock split as planned to increase the per share price of its common stock to regain compliance with the listing requirements of the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 05338F306.

06:34 EST Ault Lending files suit against Singing Machine CEO Gary Atkinson - Ault Alliance (AULT) announced that its subsidiary Ault Lending, which owns approximately 28.2% of the shares of The Singing Machine Company, Inc. (MICS) has initiated a derivative lawsuit by filing a verified complaint alleging breach of fiduciary duties relating to Singing Machine's recent sale of an aggregate of 2,197,802 shares, amounting to 34% of the shares outstanding, to Regalia Ventures, LLC and Stingray Group, Inc. (STGYF). Ault Lending alleges that the director defendants violated their fiduciary duties of care and loyalty in approving the transaction at an inadequate price following a deeply flawed process led by Singing Machine CEO Gary Atkinson, resulting in two directors, Jay B. Foreman and Mathieu Peloquin, through affiliates, holding a collective 43.2% ownership stake in MICS. The Complaint details the actions of Mr. Atkinson and the other defendant directors in the lead-up to the transaction, which Ault Lending believes demonstrate poor corporate governance and bad faith at every step: rushed negotiations run by interested parties; failure to conduct an appropriate market check and obtain an opinion from a financial advisor; refusal to appoint a special committee of independent directors to review and approve a related party transaction; improper exclusion of certain directors from board communications; inadequate notice of board meetings; refusal to engage on potential superior proposals; deciding votes cast by interested directors over the objection of other board members, and ultimately approval of a massively-dilutive transaction on financial terms detrimental to Singing Machine and its stockholders, but favorable to the directors who obtained the shares. Ault Lending is seeking declarations that the director defendants breached their fiduciary duties to stockholders, and that Stingray and Regalia Ventures aided and abetted those breaches, for the court to rescind the transaction; and an award of damages and payment of expenses. The Complaint was filed on December 21, 2023 in the Delaware Chancery Court against Singing Machine, Chief Executive Officer and director Gary Atkinson, Vice President of Global Sales and Marketing and director Bernardo Melo, and directors Jay B. Foreman, Harvey Judkowitz, Joseph Kling, and Mathieu Peloquin, Stingray Group, Inc., an affiliate of Mr. Peloquin, and Regalia Ventures, LLC, an entity owned and controlled by Mr. Foreman.

06:06 EST Opthea to receive remaining $35M under Development Funding Agreement - Opthea announced that it expects to receive the remaining $35 million committed funds under the Development Funding Agreement with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional $50 million in funding. Under the terms of the DFA, Carlyle and Abingworth committed $120 million, of which $85 million has been received to date. The remaining committed funds of $35 million and the additional $50m announced today will be received on or around December 31, 2023, bringing the total committed funding under the amended DFA to $170 million, the maximum amount allowed under the terms of the DFA. This total $85 million funding will be used to advance Opthea's Phase 3 clinical trials and pre-commercialization activities of sozinibercept for wet AMD. Under the terms of the DFA, if sozinibercept is approved in a major market, Opthea will make a milestone payment after regulatory approval and then six subsequent annual fixed success payments and variable success payments of 7% of net sales, with cumulative payments capped at four times the amount funded to Opthea. Opthea retains full worldwide commercial rights for sozinibercept and has the option to prepay its obligations in full at any time. The foregoing description of certain terms of the DFA is qualified in its entirety by reference to the full text of the Amended DFA, which will be separately filed with the Securities and Exchange Commission.

06:03 EST First Wave BioPharma to sell Niclosamide program to treat IBD - First Wave BioPharma announced that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases, or IBD, such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company. The Proposed Transaction will enable First Wave BioPharma to focus its development resources on its three late-stage clinical programs: Capeserod, a selective 5-HT4 receptor partial agonist licensed from Sanofi; Adrulipase, a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency, or EPI; and, after the closing of the recently announced potential business combination with ImmunogenX, Latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease. The non-binding term sheet includes a low seven-figure upfront payment to First Wave BioPharma for rights to Niclosamide, as well as economics related to future milestones and royalties. The transaction is expected to close in the first half of 2024. Additional details of the transaction will be disclosed upon finalization and execution of the definitive agreement. Niclosamide is a prescription, non-systemic, small molecule drug listed as an essential medicine by the World Health Organization. Niclosamide was approved by the FDA in 1982 for the treatment of intestinal tapeworm infections and has been safely used on millions of patients. The drug is a potential non-steroidal anti-inflammatory therapy for the treatment of mild-to-moderate inflammatory bowel diseases.

05:17 EST LatAmGrowth SPAC receives noncompliance notice from Nasdaq - LatAmGrowth SPAC announced that on it received a written notice from Nasdaq notifying the company that because it has not yet filed its Form 10-Q for the period ended June 30 and Form 10-Q for the period ended September 30 with the SEC, it no longer complies with Listing Rule 5250 of Nasdaq's listing rules for continued listing. Under the rules, the company now has 60 calendar days to submit a plan to regain compliance and if Nasdaq accepts the company's plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until February 20, 2024, to regain compliance. The staff noted that the company's 60 day submission date coincides with the maximum exception date of February 20, 2024.

05:13 EST Leju receives noncompliance letter from NYSE - Leju announced that it has received a letter from the NYSE, notifying the company that it is below compliance standards due to the company's total market capitalization and stockholders' equity.